Fluphenazine decanoate

Suppliers

Names

[ CAS No. ]:
5002-47-1

[ Name ]:
Fluphenazine decanoate

[Synonym ]:
Fluphenazine depot
1-decanoyloxy-2-{4-[3-(2-trifluoromethyl-phenothiazin-10-yl)-propyl]-piperazin-1-yl}-ethane
Modecate
Fluphenaline decanoate
Fluphenazindecanoat
Moditen-depo
Fluorophenazine decanoate
Dapotum D
Fluphenazine decanoate
fluphenazine O-decanoate
Flufenazine decanoate
Fluphenazindecanat
Moditen depot

Chemical & Physical Properties

[ Density]:
1.149 g/cm3

[ Boiling Point ]:
658.1ºCat 760 mmHg

[ Melting Point ]:
30-32°

[ Molecular Formula ]:
C32H44F3N3O2S

[ Molecular Weight ]:
591.77100

[ Flash Point ]:
351.8ºC

[ Exact Mass ]:
591.31100

[ PSA ]:
61.32000

[ LogP ]:
7.94050

[ Index of Refraction ]:
1.537

[ Storage condition ]:
2-8℃

[ Water Solubility ]:
Practically insoluble in water, very soluble in ethanol and in methylene chloride, freely soluble in methanol.

Toxicological Information

CHEMICAL IDENTIFICATION

RTECS NUMBER :
HE0525000
CHEMICAL NAME :
Decanoic acid, 2-(4-(3-(2-(trifluoromethyl)phenothiazin-10-yl)propyl )- 1-piperazinyl)ethyl ester
CAS REGISTRY NUMBER :
5002-47-1
LAST UPDATED :
199612
DATA ITEMS CITED :
16
MOLECULAR FORMULA :
C32-H44-F3-N3-O2-S
MOLECULAR WEIGHT :
591.85
WISWESSER LINE NOTATION :
T C666 BN ISJ EXFFF B3- AT6N DNTJ D2OV9

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
46 mg/kg/5Y-I
TOXIC EFFECTS :
Behavioral - muscle contraction or spasticity
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human
DOSE/DURATION :
179 ug/kg
TOXIC EFFECTS :
Behavioral - antipsychotic
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
21 mg/kg/6D-I
TOXIC EFFECTS :
Cardiac - pulse rate Gastrointestinal - changes in structure or function of salivary glands Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
1071 ug/kg/12D-I
TOXIC EFFECTS :
Behavioral - ataxia Lungs, Thorax, or Respiration - dyspnea Skin and Appendages - sweating
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
19 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Lungs, Thorax, or Respiration - respiratory depression Nutritional and Gross Metabolic - body temperature decrease
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
576 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - altered sleep time (including change in righting reflex) Skin and Appendages - hair
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
60 mg/kg
TOXIC EFFECTS :
Sense Organs and Special Senses (Eye) - effect, not otherwise specified Behavioral - altered sleep time (including change in righting reflex) Skin and Appendages - hair
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Rodent - rat
DOSE/DURATION :
46 mg/kg/52W-I
TOXIC EFFECTS :
Liver - changes in liver weight Kidney, Ureter, Bladder - other changes in urine composition Nutritional and Gross Metabolic - weight loss or decreased weight gain
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
SPECIES OBSERVED :
Mammal - dog
DOSE/DURATION :
82 mg/kg/52W-I
TOXIC EFFECTS :
Blood - normocytic anemia Blood - changes in bone marrow (not otherwise specified) Related to Chronic Data - changes in prostate weight
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
230 mg/kg
SEX/DURATION :
male 4 week(s) pre-mating female 2 week(s) pre-mating female 1-7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Maternal Effects - menstrual cycle changes or disorders
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
5 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - stillbirth Reproductive - Effects on Newborn - viability index (e.g., # alive at day 4 per # born alive) Reproductive - Effects on Newborn - weaning or lactation index (e.g., # alive at weaning per # alive at day 4)
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
25 mg/kg
SEX/DURATION :
female 17 day(s) after conception
TOXIC EFFECTS :
Reproductive - Fertility - pre-implantation mortality (e.g. reduction in number of implants per female; total number of implants per corpora lutea) Reproductive - Effects on Newborn - growth statistics (e.g.%, reduced weight gain) Reproductive - Effects on Newborn - delayed effects
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Intramuscular
DOSE :
5 mg/kg
SEX/DURATION :
female 7 day(s) after conception
TOXIC EFFECTS :
Reproductive - Effects on Newborn - sex ratio

MUTATION DATA

TEST SYSTEM :
Rodent - rat
DOSE/DURATION :
20 mg/kg/12W (Intermittent)
REFERENCE :
MUREAV Mutation Research. (Elsevier Science Pub. B.V., POB 211, 1000 AE Amsterdam, Netherlands) V.1- 1964- Volume(issue)/page/year: 244,331,1990 *** REVIEWS *** TOXICOLOGY REVIEW ABPYBL Advances in Biochemical Psychopharmacology. (Raven Press, 1185 Ave. of the Americas, New York, NY 10036) V.1- 1969- Volume(issue)/page/year: 9,301,1974 *** NIOSH STANDARDS DEVELOPMENT AND SURVEILLANCE DATA *** NIOSH OCCUPATIONAL EXPOSURE SURVEY DATA : NOES - National Occupational Exposure Survey (1983) NOES Hazard Code - X5576 No. of Facilities: 16 (estimated) No. of Industries: 1 No. of Occupations: 2 No. of Employees: 794 (estimated) No. of Female Employees: 419 (estimated)

Safety Information

[ Hazard Codes ]:
Xn

[ RIDADR ]:
UN 3249

[ RTECS ]:
HE0525000

[ Packaging Group ]:
II

[ Hazard Class ]:
6.1(a)

[ HS Code ]:
3003909090

Customs

[ HS Code ]: 3003909090

Articles

Adherence challenges and long-acting injectable antipsychotic treatment in patients with schizophrenia.

J. Psychosoc. Nurs. Ment. Health Serv. 51(3) , 13-8, (2013)

Medication nonadherence has been associated with persistence of psychotic symptoms, relapse, and hospitalization in patients with schizophrenia. Patients with untreated psychosis are significantly les...

Ten year outcomes of outpatients with schizophrenia on conventional depot antipsychotics: a systematic chart review.

Int. Clin. Psychopharmacol. 28(5) , 261-6, (2013)

Long-term follow-up data of patients with schizophrenia on depot antipsychotics have been few and the longest follow-up period has been up to 7 years. We carried out a systematic chart review to exami...

Differing effects of antipsychotic medications on substance abuse treatment patients with co-occurring psychotic and substance abuse disorders.

Am. J. Addict. 15(2) , 166-73, (2006)

This retrospective study of patients treated in a ninety-day, inpatient, dual-diagnosis treatment program examined antipsychotic effectiveness in this population using length of stay in treatment and ...


More Articles


Related Compounds

  • Fluphenazine decanoate N-4-oxide
  • Fluphenazine decanoate dihydrochloride
  • fluphenazine sulfoxide
  • Fluphenazine (dihydrochloride)
  • fluphenazine-N(4')-oxide
  • Fluphenazine-d8 Dihydrochloride
  • (2-Chloro-4-(4-methylpiperidine-1-carbonyl)phenyl)boronic acid
  • 2-Chloro-5-(2-methyl-4-nitrophenylcarbamoyl)benzeneboronic acid
  • (2-Fluoro-4-(isopropoxycarbonyl)phenyl)boronic acid
  • (4-((2,3-Dimethylphenyl)carbamoyl)-2-fluorophenyl)boronic acid
  • (2-Fluoro-4-(isopropylcarbamoyl)phenyl)boronic acid
  • (4-(Cyclopentylcarbamoyl)-2-fluorophenyl)boronic acid
  • 2-Chloro-5-(3-fluorobenzylcarbamoyl)phenylboronic acid
  • 2-Chloro-5-(4-methoxybenzylcarbamoyl)benzeneboronic acid
  • (2-Fluoro-3-(isopropoxycarbonyl)phenyl)boronic acid
  • (2-Fluoro-3-(propoxycarbonyl)phenyl)boronic acid
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.